

Anna Bagnato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5874551/publications.pdf>

Version: 2024-02-01

112
papers

5,786
citations

61984

43
h-index

76900

74
g-index

112
all docs

112
docs citations

112
times ranked

4855
citing authors

#	ARTICLE	IF	CITATIONS
1	The endothelin axis: emerging role in cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 110-116.	28.4	527
2	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>American Journal of Pathology</i> , 2000, 157, 1703-1711.	3.8	322
3	Endothelin 1 in cancer: biological implications and therapeutic opportunities. <i>Nature Reviews Cancer</i> , 2013, 13, 637-651.	28.4	282
4	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2000, 157, 1537-1547.	3.8	184
5	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1 α in Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 27850-27855.	3.4	182
6	The endothelin axis in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1443-1451.	2.8	172
7	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2350-2360.	7.0	167
8	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. <i>Cancer Research</i> , 2005, 65, 11649-11657.	0.9	161
9	β -Arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2806-2811.	7.1	159
10	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. <i>Molecular Pharmacology</i> , 2002, 61, 524-532.	2.3	132
11	Emerging role of endothelin-1 in tumor angiogenesis. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 44-50.	7.1	123
12	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. <i>Cancer Research</i> , 2004, 64, 1436-1443.	0.9	115
13	Role of the endothelin axis and its antagonists in the treatment of cancer. <i>British Journal of Pharmacology</i> , 2011, 163, 220-233.	5.4	103
14	Endothelin receptors as novel targets in tumor therapy. <i>Journal of Translational Medicine</i> , 2004, 2, 16.	4.4	96
15	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. <i>Journal of Biological Chemistry</i> , 2004, 279, 46700-46705.	3.4	91
16	Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. <i>Cancer Research</i> , 2003, 63, 2447-53.	0.9	90
17	Endothelin A Receptor/ β -Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. <i>Cancer Research</i> , 2014, 74, 7453-7464.	0.9	89
18	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. <i>Cancer Research</i> , 2009, 69, 2669-2676.	0.9	87

#	ARTICLE	IF	CITATIONS
19	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1 α in Human Melanoma Cells. <i>Cancer Research</i> , 2007, 67, 1725-1734.	0.9	84
20	Emerging role of the endothelin axis in ovarian tumor progression. <i>Endocrine-Related Cancer</i> , 2005, 12, 761-772.	3.1	80
21	β -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β -catenin signaling. <i>Oncogene</i> , 2013, 32, 5066-5077.	5.9	79
22	The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 473-484.	1.4	78
23	Endothelins as Autocrine Regulators of Tumor Cell Growth. <i>Trends in Endocrinology and Metabolism</i> , 1998, 9, 378-383.	7.1	74
24	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 833-842.	4.1	74
25	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1483-1492.	4.1	73
26	Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. <i>Cancer Research</i> , 2002, 62, 6381-4.	0.9	67
27	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. <i>Cancer Research</i> , 2007, 67, 6351-6359.	0.9	65
28	Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. <i>Endocrinology</i> , 1992, 130, 1097-1102.	2.8	65
29	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 41294-41301.	3.4	64
30	β -Arrestin 1 is required for endothelin-1-induced NF- κ B activation in ovarian cancer cells. <i>Life Sciences</i> , 2014, 118, 179-184.	4.3	64
31	Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis. <i>Cells Tissues Organs</i> , 2007, 185, 85-94.	2.3	63
32	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , 2013, 91, 83-94.	3.9	63
33	β -Arrestin-1 Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 523-533.	6.1	63
34	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4670-4679.	7.0	62
35	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2003-2011.	4.1	61
36	Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. <i>FASEB Journal</i> , 2000, 14, 2277-2283.	0.5	57

#	ARTICLE	IF	CITATIONS
37	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. <i>American Journal of Pathology</i> , 2003, 163, 753-762.	3.8	55
38	Endothelin A receptor drives invadopodia function and cell motility through the β -arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. <i>Oncogene</i> , 2016, 35, 3432-3442.	5.9	53
39	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1 α in Melanoma Cells. <i>PLoS ONE</i> , 2010, 5, e11241.	2.5	50
40	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. <i>Oncotarget</i> , 2016, 7, 4009-4023.	1.8	49
41	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. <i>Journal of Molecular Medicine</i> , 2013, 91, 395-405.	3.9	48
42	β -arrestin1 at the cross-road of endothelin-1 signaling in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 121.	8.6	47
43	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 2945-2957.	14.5	45
44	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. <i>Carcinogenesis</i> , 2014, 35, 840-848.	2.8	44
45	The E5 Oncoprotein of Human Papillomavirus Type 16 Enhances Endothelin-1-Induced Keratinocyte Growth. <i>Virology</i> , 1998, 248, 1-5.	2.4	41
46	β -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2019, 10, 3196.	12.8	40
47	Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. <i>Experimental and Molecular Pathology</i> , 1987, 46, 123-135.	2.1	39
48	Endothelin therapeutics in cancer: Where are we?. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R469-R475.	1.8	38
49	New Routes in GPCR/ β -Arrestin-Driven Signaling in Cancer Progression and Metastasis. <i>Frontiers in Pharmacology</i> , 2019, 10, 114.	3.5	38
50	Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584181.	3.7	35
51	Endothelin Receptor Blockade Inhibits Proliferation of Kaposi's Sarcoma Cells. <i>American Journal of Pathology</i> , 2001, 158, 841-847.	3.8	34
52	Blocking endothelin-1-receptor/ β -catenin circuit sensitizes to chemotherapy in colorectal cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 1811-1820.	11.2	34
53	Nuclear β -arrestin1 is a critical cofactor of hypoxia-inducible factor-1 α signaling in endothelin-1-induced ovarian tumor progression. <i>Oncotarget</i> , 2016, 7, 17790-17804.	1.8	33
54	Gonadotropin-Induced Expression of Receptors for Growth Hormone Releasing Factor in Cultured Granulosa Cells*. <i>Endocrinology</i> , 1991, 128, 2889-2894.	2.8	32

#	ARTICLE	IF	CITATIONS
55	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. <i>Clinical Science</i> , 2002, 103, 306S-309S.	4.3	31
56	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. <i>Biochemical and Biophysical Research Communications</i> , 1995, 209, 80-86.	2.1	29
57	Î²-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 796-801.	1.4	28
58	The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 299, R395-R404.	1.8	25
59	Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis. <i>Current Oncology</i> , 2012, 19, 36-38.	2.2	25
60	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. <i>Life Sciences</i> , 2016, 159, 43-48.	4.3	25
61	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. <i>Clinical Science</i> , 2002, 103, 302S-305S.	4.3	24
62	Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. <i>Matrix Biology</i> , 2019, 81, 17-33.	3.6	23
63	YAP and endothelin-1 signaling: an emerging alliance in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 27.	8.6	23
64	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth <i>in vitro</i> . <i>Clinical Science</i> , 2002, 103, 318S-321S.	4.3	21
65	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti-“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	4.1	21
66	Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 781-793.	2.5	21
67	hMEN1 is a key regulator in endothelin-1/Î²-arrestin1-induced invadopodial function and metastatic process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3132-3137.	7.1	21
68	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S140-S143.	1.9	20
69	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , 2013, 130, 31-37.	1.4	20
70	Modulation of adriamycin uptake by lonidamine in ehrlich ascites tumor cells. <i>Experimental and Molecular Pathology</i> , 1988, 49, 421-431.	2.1	19
71	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 782-787.	1.4	19
72	Endothelin-1 regulates hypoxia-inducible factor-1Î± and -2Î± stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. <i>Life Sciences</i> , 2014, 118, 185-190.	4.3	19

#	ARTICLE	IF	CITATIONS
73	Targeting Endothelin-1 Receptor/ β^2 -Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach. <i>Frontiers in Endocrinology</i> , 2019, 10, 609.	3.5	19
74	Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. <i>Experimental Biology and Medicine</i> , 2006, 231, 1128-31.	2.4	18
75	Targeting Endothelin Axis in Cancer. , 2004, 119, 293-314.		17
76	New insights into the regulation of the actin cytoskeleton dynamics by GPCR/ β^2 -arrestin in cancer invasion and metastasis. <i>International Review of Cell and Molecular Biology</i> , 2019, 346, 129-155.	3.2	16
77	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. <i>Life Sciences</i> , 2012, 91, 638-643.	4.3	15
78	Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. <i>Cell Reports</i> , 2021, 34, 108800.	6.4	15
79	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. <i>Life Sciences</i> , 2016, 159, 49-54.	4.3	13
80	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. <i>Communications Biology</i> , 2020, 3, 677.	4.4	13
81	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S136-S139.	1.9	12
82	Endothelin-1 receptor drives invadopodia: Exploiting how β^2 -arrestin-1 guides the way. <i>Small GTPases</i> , 2018, 9, 394-398.	1.6	12
83	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. <i>Cancer Letters</i> , 2020, 492, 84-95.	7.2	12
84	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. <i>Journal of Virology</i> , 1997, 71, 6898-6904.	3.4	12
85	Convergent pathways link the endothelin A receptor to the β^2 -catenin: The β^2 -arrestin connection. <i>Cell Cycle</i> , 2009, 8, 1461-1465.	2.6	11
86	The endothelin A receptor and epidermal growth factor receptor signaling converge on β^2 -catenin to promote ovarian cancer metastasis. <i>Life Sciences</i> , 2012, 91, 550-556.	4.3	11
87	Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. <i>Experimental Biology and Medicine</i> , 2006, 231, 1123-7.	2.4	10
88	Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. <i>Clinical Science</i> , 2002, 103, 310S-313S.	4.3	9
89	Targeting endothelin-1 receptor/ β^2 -arrestin1 network for the treatment of ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 925-932.	3.4	9
90	In reply to Schäfer <i>et al</i> : new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 1052-1055.	2.5	9

#	ARTICLE	IF	CITATIONS
91	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 600025.	2.8	9
92	Combination therapy of zibotentan with cisplatin and paclitaxel is an effective regimen for epithelial ovarian cancer. This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 676-681.	1.4	8
93	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S132-S135.	1.9	7
94	The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 2720-2733.	1.9	7
95	ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. <i>Experimental Biology and Medicine</i> , 2006, 231, 1132-5.	2.4	7
96	Targeting Endothelin Receptor Type A in Human Cervical Carcinoma Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S72-S75.	1.9	5
97	Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. <i>Cell Cycle</i> , 2009, 8, 1462-3.	2.6	5
98	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 157.	8.6	5
99	Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/ β -arr1 Axis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 764375.	3.7	4
100	Effect of hyperthermia on electron transport in ehrlich ascites tumor mitochondria. <i>Experimental and Molecular Pathology</i> , 1987, 46, 279-293.	2.1	3
101	Disrupting the endothelin and Wnt relationship to overcome chemoresistance. <i>Molecular and Cellular Oncology</i> , 2015, 2, e995025.	0.7	3
102	Methods to Investigate β -Arrestin-1/ β -Catenin Signaling in Ovarian Cancer Cells. <i>Methods in Molecular Biology</i> , 2019, 1957, 393-406.	0.9	2
103	Lost in translation: bridging the gap between cancer research and effective therapies. <i>Cell Death and Differentiation</i> , 2011, 18, 1082-1084.	11.2	1
104	Lonidamine-Induced Membrane Permeability and the Effect of Adriamycin on the Energy Metabolism of Ehrlich Ascites Tumor Cells. <i>Annals of the New York Academy of Sciences</i> , 1988, 551, 270-272.	3.8	0
105	Therapies for cancer targeting endothelin receptors. <i>Drugs of the Future</i> , 2003, 28, 983.	0.1	0
106	Abstract 698: β -arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance. , 2011, , .		0
107	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , 2011, , .		0
108	Abstract 3473: Endothelin axis autocrine loop is positively regulated by the interplay between ET-1 and hypoxia-inducible factor-1 α in melanoma cells. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract 493: Endothelin-1 induces activation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. , 2012, , .		0
110	Abstract 3086: β -arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression. , 2012, , .		0
111	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		0
112	Abstract 3144: PDZ-RhoGEF/ β -arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0